Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7243 results

Sort By:

Children and Adults With Chordoma

Study ID: NCT03910465
Start Date: 2019-04-16
End Date: 2029-12-31
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

300

Intervention / Treatment
Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Study ID: NCT06790966
Start Date: 2025-05-30
End Date: 2029-02
Study Type

Interventional

Study Phase

Phase3

No. of Participants

351

Intervention / Treatment

Combination Treatment of PDS0101 and Pembrolizumab

Pembrolizumab Monotherapy

Sponsor

PDS Biotechnology Corp.

Source: clinicaltrials.gov

Share:
Add to list

Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial

Study ID: NCT06378866
Start Date: 2024-06-03
End Date: 2029-05-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

220

Intervention / Treatment

Abiraterone

Apalutami

Biospecimen Collection

Bone Scan

Computed Tomography

Darolutami

Degarelix

Enzalutamid

Goserelin

Histrelin

Leuprolide

Magnetic Resonance Imaging

Patient Observation

Positron Emission Tomography

Prednisone

Administration questionnaire

Relugolix

Stereotactic Body Radiation Therapy

Triptorelin

Sponsor

Mayo Clinic

Source: clinicaltrials.gov

Share:
Add to list

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Study ID: NCT05592626
Start Date: 2023-01-04
End Date: 2026-10
Study Type

Interventional

Study Phase

Phase2

No. of Participants

365

Intervention / Treatment

Star ౦౬౦౨

Sponsor

Marengo Therapeutics, Inc.

Source: clinicaltrials.gov

Share:
Add to list

Concurrent Azeliragon With Craniospinal Irradiation

Study ID: NCT06724926
Start Date: 2025-02-19
End Date: 2031-01
Study Type

Interventional

Study Phase

Phase1

No. of Participants

32

Intervention / Treatment

Azeliragon

CSI

Sponsor

NYU Langone Health

Source: clinicaltrials.gov

Share:
Add to list

Building a Renewed ImaGe After Head & Neck Cancer Treatment (BRIGHT) Multi-Site RCT

Study ID: NCT05442957
Start Date: 2023-02-14
End Date: 2027-03-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

180

Intervention / Treatment

BRIGHT

Attention Control

Sponsor

Medical University of South Carolina

Source: clinicaltrials.gov

Share:
Add to list

Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial

Study ID: NCT06834126
Start Date: 2025-04-07
End Date: 2028-09-19
Study Type

Interventional

Study Phase

Phase1

No. of Participants

36

Intervention / Treatment

Biospecimen Collection

Computed Tomography

Consolidation Therapy

Functional Magnetic Resonance Imaging

Gastrointestinal Endoscopy

Magnetic Resonance Imaging

Papaverine

Radiation Therapy

Total Mesorectal Excision

Sponsor

City of Hope Medical Center

Source: clinicaltrials.gov

Share:
Add to list

[18F] F-GLN by PET/CT in Breast Cancer

Study ID: NCT03863457
Start Date: 2019-04-05
End Date: 2026-12
Study Type

Interventional

Study Phase

Phase1

No. of Participants

40

Intervention / Treatment

Fluoroglutamine [18F]F-GLN

Sponsor

Abramson Cancer Center at Penn Medicine

Source: clinicaltrials.gov

Share:
Add to list

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Study ID: NCT06425926
Start Date: 2024-05-09
End Date: 2026-11
Study Type

Interventional

Study Phase

Phase2

No. of Participants

117

Intervention / Treatment

GIM-531

Anti-PD-1 monoclonal antibody

Sponsor

Georgiamune Inc

Source: clinicaltrials.gov

Share:
Add to list

First in Human Study of TORL-3-600 in Participants With Advanced Cancer

Study ID: NCT05948826
Start Date: 2023-09-29
End Date: 2026-09-15
Study Type

Interventional

Study Phase

Phase1

No. of Participants

70

Intervention / Treatment

TORL-3-600

Sponsor

TORL Biotherapeutics, LLC

Source: clinicaltrials.gov

Share:
Add to list